Man Group plc Makes New Investment in Zymeworks Inc. $ZYME

Man Group plc acquired a new position in Zymeworks Inc. (NASDAQ:ZYME) during the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 210,779 shares of the company’s stock, valued at approximately $5,510,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. AQR Capital Management LLC boosted its position in shares of Zymeworks by 86.0% in the first quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock worth $577,000 after buying an additional 22,411 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Zymeworks by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock valued at $386,000 after buying an additional 1,427 shares in the last quarter. Jane Street Group LLC lifted its holdings in Zymeworks by 487.0% in the 1st quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock worth $1,617,000 after purchasing an additional 112,636 shares during the last quarter. Creative Planning boosted its holdings in shares of Zymeworks by 114.8% during the 2nd quarter. Creative Planning now owns 25,389 shares of the company’s stock worth $319,000 after buying an additional 13,567 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Zymeworks by 1,050.0% in the second quarter. JPMorgan Chase & Co. now owns 441,690 shares of the company’s stock valued at $5,543,000 after purchasing an additional 403,281 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Zymeworks News Roundup

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Ziihera (zanidatamab-hrii), both with and without tislelizumab plus chemotherapy, for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma. The expanded approval broadens Zymeworks’ commercial opportunity and could improve the long-term revenue outlook for its lead product. FDA approves Ziihera for first-line HER2-positive advanced gastroesophageal cancer
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $55 price target while sharply raising its earnings outlook. Its FY2026 EPS estimate increased to $1.51 from $0.31, and its FY2027 estimate moved to $1.32 from a prior loss estimate of $1.72 per share. The firm also raised several quarterly forecasts, signaling greater confidence in Ziihera-related earnings potential. HC Wainwright raises Zymeworks earnings estimates
• Positive Sentiment: Citigroup reportedly forecast substantial price appreciation, while Citizens JMP assigned Zymeworks a market outperform rating. These calls add further analyst support following the FDA decision. Citigroup forecasts strong price appreciation for Zymeworks Citizens JMP rates Zymeworks market outperform
• Neutral Sentiment: The immediate catalyst is primarily regulatory and expectations-driven; investors will likely look for prescription growth, launch execution and evidence that the approval translates into sustainable revenue and earnings.

Analyst Ratings Changes

ZYME has been the subject of a number of research analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Zymeworks in a research report on Wednesday. Wells Fargo & Company increased their target price on shares of Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on Zymeworks in a research note on Wednesday. Citizens Jmp reissued a “market outperform” rating and issued a $32.00 price target on shares of Zymeworks in a report on Wednesday. Finally, HC Wainwright boosted their price objective on Zymeworks from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Zymeworks presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

Zymeworks Price Performance

Zymeworks stock opened at $28.27 on Friday. The firm has a 50-day moving average of $24.95 and a 200-day moving average of $24.84. The company has a market cap of $2.01 billion, a price-to-earnings ratio of -14.00 and a beta of 1.15. Zymeworks Inc. has a one year low of $13.60 and a one year high of $30.62.

Zymeworks (NASDAQ:ZYME) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.The firm had revenue of $3.23 million for the quarter, compared to analyst estimates of $4.54 million. During the same quarter in the prior year, the firm earned $0.03 earnings per share. The firm’s revenue for the quarter was down 90.6% on a year-over-year basis. As a group, sell-side analysts expect that Zymeworks Inc. will post 1.37 earnings per share for the current year.

Zymeworks announced that its board has authorized a stock repurchase program on Thursday, May 14th that allows the company to buyback $125.00 million in shares. This buyback authorization allows the company to repurchase up to 7% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.